Global Omics Lab Services Market Size study, by Services (Genomics, Proteomics), Business (Hospitals), Frequency of Service (One-off), Product, End-use and Regional Forecasts 2022–2032

Global Omics Lab Services Market is valued approximately at USD 69 billion in 2023 and is anticipated to grow with a dynamic compound annual growth rate of more than 13.72% over the forecast period 2024–2032. Omics lab services have taken center stage in modern biomedical science, providing unparalleled insights into the cellular and molecular intricacies that underpin health and disease. Encompassing genomics, proteomics, transcriptomics, metabolomics, and more, these services allow for comprehensive profiling of biological systems, paving the way for personalized medicine, early diagnostics, and precision therapeutics. In an era increasingly characterized by data-driven medicine, omics technologies have transformed from academic tools to clinical necessities, redefining how diseases are predicted, prevented, and treated at the population and individual levels.

The market’s trajectory is being accelerated by the rising burden of chronic conditions, such as cancer, cardiovascular disorders, and metabolic syndromes, which require early, tailored interventions. Healthcare institutions and research entities are aggressively integrating omics platforms to decode disease patterns and inform targeted treatment strategies. Moreover, the ongoing convergence of high-throughput sequencing, mass spectrometry, and artificial intelligence is making omics workflows more cost-effective, scalable, and clinically actionable. Simultaneously, one-off testing models are witnessing significant demand growth, especially among hospital networks, which are turning to external lab partners for rapid, high-complexity diagnostics to support care decision-making.

Despite its disruptive potential, the omics lab services market must contend with considerable headwinds. High capital costs, ethical concerns around genomic data, regulatory disparities across regions, and a global shortage of skilled bioinformaticians present structural barriers to wider adoption. Nonetheless, these challenges are spurring innovation in workflow automation, cloud-based analytical platforms, and collaborative business models that merge service delivery with proprietary bioinformatics solutions. As more governments and insurers recognize the value of preventive, precision diagnostics, public-private partnerships and clinical integration are becoming key market enablers.

As competitive dynamics intensify, industry frontrunners are doubling down on technology acquisitions, joint ventures, and strategic licensing agreements to diversify portfolios and deepen end-user engagement. Multi-omics integration is gaining traction as it offers a holistic view of disease mechanisms and facilitates robust biomarker discovery. Companies are also investing heavily in quality control systems, interoperability frameworks, and regulatory certifications to meet rising compliance standards in hospital-based and academic settings. These evolutions are not only driving operational efficiencies but also enhancing the clinical utility and economic value proposition of omics services.

Regionally, North America continues to dominate the global omics lab services landscape, underpinned by well-established healthcare infrastructure, significant R&D investments, and early adoption of genomics-based medicine. The United States, in particular, remains a hub for clinical genomics trials and large-scale cohort studies. Europe, following closely, is advancing through robust national genomics initiatives, especially in the UK, Germany, and the Nordics. Meanwhile, the Asia Pacific region is emerging as the fastest-growing market, fueled by expanding healthcare access, rising prevalence of chronic disease, and favorable government-led genome sequencing programs in China, India, and Japan. Latin America and the Middle East & Africa are gradually advancing, with regional genomics hubs beginning to support translational research and cross-border service outsourcing.

Major market player included in this report are:
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• PerkinElmer Inc.
• Eurofins Scientific SE
• BGI Genomics Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Oxford Nanopore Technologies
• Bruker Corporation
• GenScript Biotech Corporation
• Myriad Genetics, Inc.
• Charles River Laboratories International, Inc.

The detailed segments and sub-segmens of the market are explained below:

By Services
• Genomics
• Proteomics

By Business
• Hospitals

By Frequency of Service
• One-off

By Product
• Instruments
• Consumables
• Software

By End-use
• Clinical Diagnostics
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.